Cocrystal Pharma Inc
COCP0.990USD
-0.010-1.00%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
12.91MMarket Cap
LossP/E TTM
More Details of Cocrystal Pharma Inc Company
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Cocrystal Pharma Inc Info
Ticker SymbolCOCP
Company nameCocrystal Pharma Inc
IPO dateMar 12, 2018
CEOMartin (James J)
Number of employees11
Security typeOrdinary Share
Fiscal year-endMar 12
Address19805 N Creek Pkwy
CityBOTHELL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98011-8251
Phone17864591831
Websitehttps://www.cocrystalpharma.com/
Ticker SymbolCOCP
IPO dateMar 12, 2018
CEOMartin (James J)
Company Executives of Cocrystal Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.38M
+35.29%
Dr. Roger D. Kornberg, Ph.D.
Dr. Roger D. Kornberg, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.82K
--
Mr. Steven D. (Steve) Rubin
Mr. Steven D. (Steve) Rubin
Independent Director
Independent Director
11.43K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Ms. Jody Cain
Ms. Jody Cain
Investor Relations
Investor Relations
--
--
Dr. Sam Lee, Ph.D.
Dr. Sam Lee, Ph.D.
Co-Chief Executive Officer, President
Co-Chief Executive Officer, President
--
--
Mr. James J. Martin
Mr. James J. Martin
Co-Chief Executive Officer, Chief Financial Officer
Co-Chief Executive Officer, Chief Financial Officer
--
--
Dr. Phillip Frost, M.D.
Dr. Phillip Frost, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony J. Japour, M.D.
Dr. Anthony J. Japour, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.38M
+35.29%
Dr. Roger D. Kornberg, Ph.D.
Dr. Roger D. Kornberg, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.82K
--
Mr. Steven D. (Steve) Rubin
Mr. Steven D. (Steve) Rubin
Independent Director
Independent Director
11.43K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Ms. Jody Cain
Ms. Jody Cain
Investor Relations
Investor Relations
--
--
Dr. Sam Lee, Ph.D.
Dr. Sam Lee, Ph.D.
Co-Chief Executive Officer, President
Co-Chief Executive Officer, President
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frost Gamma Investments Trust
12.44%
Hassan (Fred)
10.00%
Schinazi (Raymond F)
4.62%
Wilcox (Sue)
4.10%
The Vanguard Group, Inc.
1.94%
Other
66.89%
Shareholders
Shareholders
Proportion
Frost Gamma Investments Trust
12.44%
Hassan (Fred)
10.00%
Schinazi (Raymond F)
4.62%
Wilcox (Sue)
4.10%
The Vanguard Group, Inc.
1.94%
Other
66.89%
Shareholder Types
Shareholders
Proportion
Individual Investor
20.03%
Corporation
12.44%
Investment Advisor
2.63%
Investment Advisor/Hedge Fund
1.00%
Hedge Fund
0.95%
Research Firm
0.24%
Other
62.70%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
36
665.03K
5.13%
--
2025Q3
37
665.03K
5.42%
-21.53K
2025Q2
35
686.57K
7.46%
-62.26K
2025Q1
34
748.82K
7.65%
-29.18K
2024Q4
34
711.44K
7.72%
-7.89K
2024Q3
38
719.33K
7.75%
+30.83K
2024Q2
46
674.41K
8.31%
-47.20K
2024Q1
51
721.61K
7.97%
-89.73K
2023Q4
55
683.66K
8.36%
-20.88K
2023Q3
59
705.97K
8.18%
+37.34K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frost Gamma Investments Trust
1.34M
10.24%
+15.24K
+1.15%
Sep 30, 2025
Hassan (Fred)
1.02M
7.82%
--
--
Apr 29, 2025
Schinazi (Raymond F)
637.06K
4.89%
--
--
Apr 29, 2025
Wilcox (Sue)
564.95K
4.33%
--
--
Apr 29, 2025
The Vanguard Group, Inc.
268.08K
2.06%
-7.58K
-2.75%
Jun 30, 2025
Renaissance Technologies LLC
125.03K
0.96%
-600.00
-0.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
73.10K
0.56%
-19.00
-0.03%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
73.75K
0.57%
--
--
Jun 30, 2025
Lee (Sam Ph.D.)
56.35K
0.43%
--
--
Apr 29, 2025
Kornberg (Roger D)
53.82K
0.41%
--
--
Apr 29, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 10, 2022
Merger
12→1
Oct 10, 2022
Merger
12→1
Oct 10, 2022
Merger
12→1
Oct 10, 2022
Merger
12→1
Date
Type
Ratio
Oct 10, 2022
Merger
12→1
Oct 10, 2022
Merger
12→1
Oct 10, 2022
Merger
12→1
Oct 10, 2022
Merger
12→1
FAQs
Who are the top five shareholders of Cocrystal Pharma Inc?
The top five shareholders of Cocrystal Pharma Inc are:
Frost Gamma Investments Trust holds 1.34M shares, accounting for 10.24% of the total shares.
Hassan (Fred) holds 1.02M shares, accounting for 7.82% of the total shares.
Schinazi (Raymond F) holds 637.06K shares, accounting for 4.89% of the total shares.
Wilcox (Sue) holds 564.95K shares, accounting for 4.33% of the total shares.
The Vanguard Group, Inc. holds 268.08K shares, accounting for 2.06% of the total shares.
Frost Gamma Investments Trust holds 1.34M shares, accounting for 10.24% of the total shares.
Hassan (Fred) holds 1.02M shares, accounting for 7.82% of the total shares.
Schinazi (Raymond F) holds 637.06K shares, accounting for 4.89% of the total shares.
Wilcox (Sue) holds 564.95K shares, accounting for 4.33% of the total shares.
The Vanguard Group, Inc. holds 268.08K shares, accounting for 2.06% of the total shares.
What are the top three shareholder types of Cocrystal Pharma Inc?
The top three shareholder types of Cocrystal Pharma Inc are:
Frost Gamma Investments Trust
Hassan (Fred)
Schinazi (Raymond F)
Frost Gamma Investments Trust
Hassan (Fred)
Schinazi (Raymond F)
How many institutions hold shares of Cocrystal Pharma Inc (COCP)?
As of 2025Q4, 36 institutions hold shares of Cocrystal Pharma Inc, with a combined market value of approximately 665.03K, accounting for 5.13% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.29%.
What is the biggest source of revenue for Cocrystal Pharma Inc?
In --, the -- business generated the highest revenue for Cocrystal Pharma Inc, amounting to -- and accounting for --% of total revenue.
